Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections

doi:10.3748/wjg.v28.i11.1172

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4608)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

312

WORD

121

HTML

2316

Figures (1-4)

252

Tables (1-1)

248

Sum=3249

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

204

Download

381

Sum=585

Publishing Process of This Article

Item

Count

Browse

272

Download

502

Sum=774

Mar 21, 2022 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Mar 21, 2022; 28(11): 1172-1183
Published online Mar 21, 2022. doi: 10.3748/wjg.v28.i11.1172

Full Size Figure Download Figure

Figure 4 Comparisons of sequential changes of median eGFR from baseline, during DAA course, SVR12, and post-SVR12 stratified by SOF/TDF, SOF/TAF, SOF/non-TDF/non-TAF, non-SOF/TDF, non-SOF/TAF, and non-SOF/non-TDF/non-TAF regimens. eGFR: Estimated glomerular filtration rate; DAA: Direct-acting antivirals; SVR12: Sustained virologic response 12 wk off-therapy; SOF: Sofosbuvir; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir alafenamide.

Citation: Sun HY, Cheng CY, Lin CY, Yang CJ, Lee NY, Liou BH, Tang HJ, Liu YM, Lee CY, Chen TC, Huang YC, Lee YT, Tsai MJ, Lu PL, Tsai HC, Wang NC, Hung TC, Cheng SH, Hung CC. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. World J Gastroenterol 2022; 28(11): 1172-1183
URL: https://www.wjgnet.com/1007-9327/full/v28/i11/1172.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i11.1172